Anticancer peptides

A peptide of formula (I) or a pharmaceutical salt thereof:

• wherein
• “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1;
• and
• “r” is an integer from 1 to 10;
• the peptide comprising:
• a linker biradical “L” of formula (II)
• —[(R1)a—(R2)—(R3)b]c— (II)
• which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I),
• a C-terminal end corresponding to —C(O)R4;
• and
• a N-terminal end corresponding to —NHR5;
• wherein.
• “a” and “b” are the same or different and are 0 or 1;
• “c” is comprised an integer from 1 to 10;
• R1 and R3 are biradicals independently selected from the group consisting of:
• (C1-C10)alkyl;
• (C1-C10)alkyl substituted by one or more radicals selected from the group consisting of:
• halogen, (C1-C10)alkyl, —OR6, —NR7R8, —SR9, —SO2R11, and —CO2R12;
• (C2-C10)alkenyl;
• (C2-C10)alkenyl substituted by one or more radicals selected from the group consisting of:
• halogen, (C1-C10)alkyl, —OR6, —NR7R8, —SR9, —SO2R11, and —CO2R11;
• (C2-C10)alkynyl;
• and (C2-C10)alkinyl substituted by one or more radicals selected from the group consisting of:
• halogen, (C1-C10)alkyl, —OR6, —NR7R8, —SR9, —SO2R11, and —CO2R12;
• R2 is a biradical selected from the group consisting of:
• —O—, C(═O), C(═O )NR13, C(═O)O, S(═O), S(═O)2, NR14, (C2-C10)alkenyl, (C2-C10)alkynyl, —S—S—, and a known ring system comprising from 3 to 14 members, the system comprising from 1 to 3 rings, where:
• each one of the rings is saturated, partially unsaturated, or aromatic;
• the rings are isolated, partially or totally fused,
• each one of the members forming the known ring system is selected from the group consisting of:
• —CH—, —CH2—, —NH—, —SH—, —S—, and —O—;
• and
• the ring system is optionally substituted by one or more radicals independently selected from the group consisting of halogen, —OH, —NO2, (C1-C10)alkyl, (C1-C10)haloalkyl, and (C1-C10)alkyl-O-—;
• and
• R4 is a radical selected from the group consisting of —OH and —NR17R18;
• R5 is a radical selected from the group consisting of —H and (C1-C10)alkyl;
• R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and R18 are radicals independently selected from the group consisting of:
• —H and (C1-C10)alkyl;
• and
• the amino acids which are connected by the linker being of formula (III)
• wherein
• R19 is a monoradical selected from the group consisting of:
• (C1-C10)alkyl, (C2-C10)alkenyl, (C2-C10)alkynyl, and a known ring system comprising from 3 to 14 members, the system comprising from 1 to 3 rings, where:
• each one of the rings is saturated, partially unsaturated, or aromatic;
• the rings are isolated, partially or totally fused,
• each one of the members forming the known ring system is selected from the group consisting of:
• —CH—, —CH2—, —NH—, —N—, —SH—, —S—, and —O—;
• or, alternatively, a peptide or pharmaceutical acceptable salt thereof having an identity of at least 85% with the peptide of sequence SEQ ID NO:
• 18
• wherein
• L is a linker biradical of formula (II) as defined above, and
• X is an amino acid of formula (III), as defined above.